Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boulder/denver blog main
boulder/denver top stories
crispr
7
×
detroit blog main
detroit top stories
life sciences
national
national blog main
national top stories
7
×
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
7
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
indiana blog main
indiana top stories
ipo
cancer
fda
novartis
biogen
deals
eli lilly
glaxosmithkline
startups
abbvie
cancer immunotherapy
clinical trials
What
bio
roundup
life
moves
new
science
ceo
companies
crispr
ipo
millions
remains
talk
therapeutics
week
years
acquisitions
allogene
announced
approval
bails
becker
big
billions
biogen’s
biopharmaceutical
black
bosley's
bosley’s
brand
bridge
bridgebio
bucks
cancer
capital
car
cas
collabs
continue
convo
Language
unset
Current search:
crispr
×
biotech
×
" national top stories "
×
" seattle blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More